Browse > Article
http://dx.doi.org/10.5487/TR.2013.29.3.217

Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay  

Kim, Ji Won (Department of Pharmacology, CKD Research Institute)
Ahn, Ilyoung (Toxicological Screening and Testing Division, National Institute of Food and Drug Safety Evaluation)
Ryu, Sung Ha (College of Pharmacy, Dankook University)
Jeon, Hong Ryeol (CTC BIO Inc.)
Lee, Bong Sang (CTC BIO Inc.)
Kim, Kyu-Bong (College of Pharmacy, Dankook University)
Publication Information
Toxicological Research / v.29, no.3, 2013 , pp. 217-219 More about this Journal
Abstract
Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 ${\mu}g$/plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.
Keywords
Hypertension; Olmesartan cilexetil; Angiotension II receptor antagonist; Mutagenicity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 He, J. and Whelton, P.K. (1997) Epidemiology and prevention of hypertension. Med. Clin. North Am., 81, 1077-1097.   DOI   ScienceOn
2 Whelton, P.K. (1994) Epidemiology of hypertension. Lancet, 344, 101-106.   DOI   ScienceOn
3 Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K. and He, J. (2005) Global burden of hypertension: analysis of worldwide data. Lancet, 365, 217-223.   DOI   ScienceOn
4 Brunner, H.R. (2006) Olmesartan medoxomil: current status of its use in monotherapy. Vasc. Health Risk Manage., 2, 327-340.   DOI
5 Fletcher, A.E., Palmer, A.J. and Bulpitt, C.J. (1994) Cough with angiotensin converting enzyme inhibitors: how much of a problem? J. Hypertens. Suppl., 12, S43-S47.
6 Vleeming, W., van Amsterdam, J.G., Stricker, B.H. and de Wildt, D.J. (1998) ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf., 18, 171-188.   DOI   ScienceOn
7 Warner, G.T. and Jarvis, B. (2002) Olmesartan medoxomil. Drugs, 62, 1354-1356.   DOI   ScienceOn
8 Mizuno, M., Sada, T., Ikeda, M., Fukuda, N., Miyamoto, M., Yanagisawa, H. and Koike, H. (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol., 285, 181-188.   DOI   ScienceOn
9 OECD/OCDE. (1997) OECD guidelines for the testing of chemicals (No. 471), Bacterial Reverse Mutation Test, pp. 1-11.
10 Norwood, D., Branch, E.I., Smith, B. and Honeywell, M. (2002) Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast., 27, 611-618.
11 Schwocho, L.R. and Masonson, H.N. (2001). Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J. Clin. Pharmacol., 41, 515-527.   DOI   ScienceOn
12 Puchler, K., Nussberger, J., Laeis, P., Wittem, P.U. and Brunner, H.R. (1997) Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist in saltrestricted hypertensive patients. J. Hypertens., 15, 1809-1812.   DOI
13 Brambilla, G. and Martelli, A. (2006) Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat. Res., 612, 115-149.   DOI   ScienceOn